University of Notre Dame DU Lac raised its stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 3.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 82,503 shares of the medical research company’s stock after purchasing an additional 2,368 shares during the quarter. University of Notre Dame DU Lac owned 0.24% of Genomic Health worth $2,648,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Eagle Asset Management Inc. boosted its holdings in Genomic Health by 18.4% during the second quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock valued at $12,351,000 after purchasing an additional 58,920 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Genomic Health by 10.9% during the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock valued at $26,473,000 after purchasing an additional 80,100 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Genomic Health by 26.1% during the second quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock valued at $12,070,000 after purchasing an additional 76,758 shares in the last quarter. FMR LLC boosted its holdings in Genomic Health by 3.1% during the second quarter. FMR LLC now owns 253,948 shares of the medical research company’s stock valued at $8,266,000 after purchasing an additional 7,600 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Genomic Health by 6.8% during the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock valued at $54,379,000 after purchasing an additional 106,452 shares in the last quarter. 89.76% of the stock is currently owned by institutional investors.

In other news, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $31.00, for a total value of $155,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. Insiders sold 21,379 shares of company stock valued at $676,131 in the last quarter. 46.20% of the stock is currently owned by corporate insiders.

Genomic Health, Inc. (GHDX) opened at $29.83 on Wednesday. Genomic Health, Inc. has a one year low of $26.37 and a one year high of $34.02.

A number of research firms have weighed in on GHDX. Jefferies Group reaffirmed a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a report on Friday, October 20th. Zacks Investment Research raised Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, October 13th. Cowen reaffirmed a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a report on Friday, September 1st. Canaccord Genuity reaffirmed a “buy” rating and set a $35.00 price objective on shares of Genomic Health in a report on Wednesday, September 27th. Finally, BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $32.67.

ILLEGAL ACTIVITY WARNING: “University of Notre Dame DU Lac Buys 2,368 Shares of Genomic Health, Inc. (GHDX)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/university-of-notre-dame-du-lac-buys-2368-shares-of-genomic-health-inc-ghdx/1746827.html.

Genomic Health Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.